Fever-range hyperthermia vs. hypothermia effect on cancer cell viability, proliferation and HSP90 expression

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Kalamida, Dimitra ^a   Karagounis, Ilias V ^a   Mitrakas, Achilleas ^a   Kalamida, Sofia ^a   Giatromanolaki, Alexandra ^a   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CISPLATIN; HEAT SHOCK PROTEIN 90; KI 67 ANTIGEN; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FETUS; FEVER RANGED HYPERTHERMIA; FIBROBLAST; HEAT SENSITIVITY; HUMAN; HUMAN CELL; HYPERTHERMIA; HYPOTHERMIA; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; CELL SURVIVAL; COLD; COLD SHOCK RESPONSE; COMPARATIVE STUDY; DRUG SCREENING; HEAT; HEAT SHOCK RESPONSE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COLD TEMPERATURE; COLD-SHOCK RESPONSE; DACARBAZINE; DRUG SCREENING ASSAYS, ANTITUMOR; HEAT-SHOCK RESPONSE; HOT TEMPERATURE; HSP90 HEAT-SHOCK PROTEINS; HUMANS;

EID: 84922387480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116021     Document Type: Article

References (27)

1. Fiorentini G, Szasz A (2006) Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther 2: 41-46. doi: 10.4103/0973-1482.25848 PMID: 17998673
2. Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, et al. (2010) European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO), Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11: 561-570. doi: 10.1016/S1470-2045(10)70071-1 PMID: 20434400
3. Bull JM, Scott GL, Strebel FR, Nagle VL, Oliver D, et al. (2008) Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol. Int J Hyperthermia 24: 649-662. doi: 10.1080/02656730802104740 PMID: 18608594
4. Rowe RW, Strebel FR, Proett JM, Deng W, Chan D, et al. (2010) Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia. 26:565-576. doi: 10.3109/02656736.2010.483635 PMID: 20707651
5. Iwata K, Shakil A, Hur WJ, Makepeace CM, Griffin RJ, et al. (1996) Tumour pO2 can be increased markedly by mild hyperthermia. Br J Cancer Suppl 27: S217-221. PMID: 8763884
6. Vidair CA, Dewey WC (1988) Two distinct modes of hyperthermic cell death. Radiat Res 116: 157-171. doi: 10.2307/3577486 PMID: 2460896
7. Lepock JR, Frey HE, Ritchie KP (1993) Protein denaturation in intact hepatocytes and isolated cellular organelles during heat shock. J Cell Biol 122: 1267-1276. doi: 10.1083/jcb.122.6.1267 PMID: 8376462
8. Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, et al. (2011) Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 108:9851-9856. doi: 10.1073/pnas.1101053108 PMID: 21555554
9. Skitzki JJ, Repasky EA, Evans SS (2009) Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. 10:550-558. PMID: 19513944
10. Repasky EA, Evans SS, Dewhirst MW (2013) Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res 1:210-216. doi: 10.1158/2326-6066.CIR-13-0118 PMID: 24490177
11. Morimoto RI (1998) Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulator. Genes Dev 12: 3788-3796. doi: 10.1101/gad.12.24.3788 PMID: 9869631
12. Lindquist S (1986) The heat-shock response. Annu Rev Biochem 55: 1151-1191. doi: 10.1146/annurev.bi.55.070186.005443 PMID: 2427013
13. Pratt WB, Morishima Y, Peng HM, Osawa Y (2010) Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med 235:278-289. doi: 10.1258/ebm.2009.009250
14. Zachari MA, Chondrou PS, Pouliliou SE, Mitrakas AG, Abatzoglou I, et al. (2014) Evaluation of the AlamaBlue assay for adherent cells irradiation experiments. Dose-Response. 12:246-58. doi: 10.2203/dose-response.13-024.Koukourakis PMID: 24910583
15. Page B, Page M, Noel C (1993) A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol 3:473-476. PMID: 21573387
16. Morrissey JJ, Higashikubo R, Goswami PC, Dixon P (2009) Mild hyperthermia as a potential mechanism to locally enhance cell growth kinetics. J Drug Target 17: 719-723. doi: 10.3109/10611860903074968 PMID: 19845488
17. Armour EP, McEachern D, Wang Z, Corry PM, Martinez A, et al. (1993) Sensitivity of human cells to mild hyperthermia. Cancer Res 53: 2740-2744. PMID: 8504414
18. Matijasevic Z (2002) Selective protection of non-cancer cells by hypothermia. Anticancer Res 22: 3267-3272. PMID: 12530074
19. Nias AH, Perry PM, Photiou AR (1988) Modulating the oxygen tension in tumours by hypothermia and hyperbaric oxygen. J R Soc Med 81: 633-636. PMID: 3210193
20. Sealy R, Harrison GG, Morrell D, Korrubel J, Gregory A, et al. (1986) A feasibility study of a new approach to clinical radiosensitisation: hypothermia and hyperbaric oxygen in combination with pharmacological vasodilatation. Br J Radiol 59: 1093-1098. doi: 10.1259/0007-1285-59-707-1093 PMID: 3790896
21. Zhang XM, Lv YG, Chen GB, Zou Y, Lin CW, et al. (2012) Effect of mild hypothermia on breast cancer cells adhesion and migration. Biosci Trends 6: 313-324. PMID: 23337791
22. Twiddy D, Cain K (2007) Caspase-9 cleavage, do you need it? Biochem J 405(Pt 1): e1. doi: 10.1042/BJ20070617 PMID: 17555401
23. Susin SA, Lorenzo HK, Zamzami N (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446. doi: 10.1038/17135 PMID: 9989411
24. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, et al. (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67:2932-2937. doi: 10.1158/0008-5472.CAN-06-4511 PMID: 17409397
25. Barrott JJ, Haystead TAJ (2013) Hsp90, an unlikely ally in the war on cancer. FEBS Journal 280: 1381-1396. doi: 10.1111/febs.12147 PMID: 23356585
26. Mauz-Körholz C, Dietzsch S, Schippel P, Banning U, Körholz D (2003) Molecular mechanisms of hyperthermia- and cisplatin-induced cytotoxicity in T cell leukemia. Anticancer Res. 23(3B):2643-2647. PMID: 12894552
27. Amichetti M, Graiff C, Fellin G, Pani G, Bolner A, et al. (1993) Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: A phase I-II study. Int J Rad Oncol 26:801-807. doi: 10.1016/0360-3016(93)90495-H